Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (NASDAQ: MYL) and Teva does not intend to continue to … · 7/27/2015
Previously Teva acquired 1.35 percent of Mylan NV’s stock in an effort to force the company to accept the already rejected $41 billion bid. After securing the deal with Allergan, Teva said it will review its options on the … · 7/28/2015
Mr. Vigodman added that Teva will drop its pursuit of rival Mylan NV (NASDAQ:MYL), which it had proposed to buy on April 21. Overall, the news shot the stock up as Teva shares rallied 16% in trading on July 27 …
Investopedia · 7/28/2015
Mylan has gotten slammed, but buyers are stepping in ... unusual option activity on optionMONSTER's ActionTracker data system. optionMONSTER® provides stock market insight, advanced options education, and actionable trade ideas to meet the …
Option MONSTER · 7/28/2015
In addition, 480 stocks hit 52-week lows on the New York Stock Exchange, the most in one day since Oct ... giving up on its bid to buy Mylan. Allergan rose 6.09 percent while Mylan fell 14.51 percent. Fiat Chrysler fell … · 7/28/2015
Mylan touts regulatory clearance to buy Perrigo Mylan said Wednesday ... Bayer plans to spin off that business through a stock market flotation, and it will operate under a new name, Covestro, beginning Sept. 1. North American sales for Bayer ...
Pittsburgh Post-Gazette · 1 day ago
Israel’s Teva Pharmaceutical Industries this week gave up its hostile takeover bid of rival Mylan, according to reports. Instead, Teva will purchase Allergan’s generic drugs business for $40.5 billion in cash and stock. The deal is the biggest in ...
The Jewish Chronicle · 1 day ago
Tel Aviv: Israel’s Teva Pharmaceutical Industries Ltd will pay $40.5 billion in cash and stock for Allergan Inc.’s generic drugs ... Teva, which dropped its hostile pursuit of Mylan NV, will likely have to sell off some …
Live Mint · 7/28/2015
Mylan NV (NASDAQ: MYL) shares declined 13.7% to $56.92. Teva Pharmaceutical Industries dropped its $40-billion cash and stock bid for Mylan. Share volume was 21.7 million, compared to an all-day average of 5.5 million
BayStreet · 7/27/2015
To pay $33.75 billion in cash, 10 pct of Teva's shares TEL AVIV, July 27 (Reuters) - Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal ... hostile bid for Mylan , which had ...
Reuters · 7/27/2015


Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase